Browse the evidence

Oral semaglutide is increasingly preferred by younger female patients with fewer comorbidities compared to subcutaneous semaglutide.

If you are a younger woman with few other health issues, you might be more likely to be prescribed oral semaglutide. This form is taken daily as a pill, which some patients prefer over weekly injections. Ensure you follow the specific administration instructions for oral semaglutide (taken on an empty stomach with water) to ensure effectiveness.

Abnormal adiposity is the dominant causal driver of cardiometabolic disease, and targeting it as the primary intervention simplifies management and reduces the need for concurrent pharmacotherapy for downstream drivers like hypertension and dyslipidemia.

Focus on weight loss as the primary treatment for high blood pressure, high blood sugar, and high cholesterol. Instead of taking multiple medications for each issue, prioritize lifestyle changes or weight-loss medications to reduce body fat, as this addresses the root cause that drives all other metabolic risks.

Glucagon receptor agonism (GCGRA), particularly in triagonists like retatrutide, increases energy expenditure and enhances weight loss efficacy compared to GLP-1/GIP agonists alone, though it carries risks of adverse events like tachycardia.

Triagonist medications (combining GLP-1, GIP, and Glucagon effects) can achieve higher weight loss (up to 24%) than current GLP-1 drugs by actively increasing how many calories you burn, not just by reducing appetite. While these drugs can cause side effects like rapid heart rate, doctors can manage this by starting with very low doses and increasing them slowly. This approach offers a more sustainable path to weight loss by counteracting the body's tendency to slow down metabolism.

Lean MASLD (normal BMI but with metabolic dysfunction) is a distinct phenotype driven by sarcopenia, adverse fat distribution, and genetic susceptibility, requiring different treatment strategies than obesity-driven MASLD.

If you have a normal BMI but metabolic issues (like high blood sugar or blood pressure), you can still develop fatty liver disease. This 'lean MASLD' is often linked to low muscle mass and genetics. Focus on building muscle and managing metabolic health rather than just losing weight.

Baseline diet quality in weight loss trial participants is characterized by high saturated fat intake (median 12.1% of energy) and low dietary fiber (median 17.0 g/day), indicating a need for interventions to prioritize diet quality over simple energy restriction.

If you are trying to lose weight, do not just count calories or cut fat. Look at what kind of fat and carbs you are eating. Your baseline diet likely has too much saturated fat and not enough fiber. To improve your health outcomes, especially for heart disease and diabetes risk, you must improve the quality of your diet (more fiber, better fats) alongside any weight loss efforts.

Black race and younger age are significantly associated with lower diet quality scores (AHEI-2010 and DASH) in this population, highlighting racial disparities in baseline diet quality.

If you are Black or younger, you may face specific challenges in maintaining a high-quality diet. The study shows these groups often have lower diet quality scores. Interventions should be tailored to address these specific disparities, such as improving access to healthy foods and culturally relevant nutrition education.

Metabolic surgery (specifically Roux-en-Y Gastric Bypass and Sleeve Gastrectomy) yields significantly higher diabetes remission rates compared to intensive lifestyle interventions or medical therapy alone.

For eligible patients (BMI >= 35, or >= 27 with comorbidities), metabolic surgery (RYGB or Sleeve Gastrectomy) offers the highest chance of type 2 diabetes remission, significantly outperforming lifestyle changes or medication alone. While upfront costs and surgical risks exist, laparoscopic techniques have made it safer, and it reduces long-term healthcare costs by resolving other obesity-related conditions. Early intervention (shorter diabetes duration) improves success rates.

In drug-naive individuals with early type 2 diabetes, sitagliptin treatment (100 mg daily) reduces postprandial glucose excursions regardless of whether the meal is carbohydrate-rich, protein-rich, or lipid-rich.

If you have early type 2 diabetes and take sitagliptin, your blood sugar response to meals is improved regardless of whether you eat carbs, protein, or fat. While protein and fat-rich meals naturally cause smaller blood sugar spikes, the medication helps manage glucose levels across all meal types. This makes dietary flexibility easier, as you don't need to strictly avoid carbohydrates to benefit from the drug's glucose-lowering effects.

Dietary weight loss interventions result in a consistent percentage of lean mass loss (approximately 29-30%) regardless of the total magnitude of weight lost, provided the loss exceeds 5% of baseline body weight.

If you lose weight through diet, expect to lose about 30% of that weight as lean mass, regardless of whether you lose 5% or 15% of your body weight. This is a consistent biological response to caloric restriction, not a failure of your diet. To mitigate this, incorporate resistance training, as the paper notes this is a benchmark for 'dietary modifications' without medication.

Dietary weight loss stabilizes the proportion of lean mass lost (%LML) at approximately 25-33% once total weight loss exceeds 5%, contradicting the hypothesis that lean loss increases proportionally with greater weight loss.

When you lose weight through diet, you will lose some muscle along with fat. This is normal and accounts for about 25-33% of the total weight lost, regardless of how much weight you lose. Men tend to lose a slightly higher percentage of lean mass than women. To minimize this, combine your diet with resistance training and adequate protein intake, but do not fear that larger weight loss equals disproportionately larger muscle loss.

Diet-based weight loss interventions result in minimal loss of appendicular lean soft tissue (a surrogate for skeletal muscle), with losses accounting for less than 10% of total mass loss after adjusting for fat-free adipose tissue.

If you are losing weight through diet alone (without resistance training), you will not lose significant muscle mass. The study found that lean tissue loss was minimal (less than 10% of total weight lost) and that your muscle mass relative to your new body size actually increased. You do not need to fear muscle loss as a barrier to starting a diet.

Total daily energy expenditure (TDEE) declines significantly with age in both males and females, primarily driven by reductions in fat-free mass and increases in fat mass, with the most substantial drop occurring during the transition from middle age to older adulthood.

Your daily calorie needs drop as you age, especially after 55. This isn't just 'hormones'; it's largely because you lose muscle (fat-free mass) and gain fat. To maintain your weight, you must adjust your caloric intake or increase activity to match this lower expenditure. Focus on preserving muscle mass through resistance training to keep your metabolic rate higher.

Females have a higher percentage of body fat and fat mass, and lower fat-free mass compared to males across all age groups, but the trajectory of body composition change with age is similar between sexes.

Women naturally carry more fat and less muscle than men, which lowers their baseline calorie needs. However, as you age, your body composition changes (losing muscle, gaining fat) in a pattern very similar to men. Focus on strength training to preserve muscle mass; this is the most effective way to counteract the age-related drop in energy expenditure for both sexes.

Thyroid dysfunction and structural changes caused by overnutrition are largely reversible through weight loss and return to a normal diet.

If you have obesity-related thyroid issues, know that they are likely reversible. Losing weight through diet and lifestyle changes can restore normal thyroid function and hormone levels.

Tirzepatide demonstrates high clinical efficacy but has a higher Incremental Cost-Effectiveness Ratio (ICER), making its cost-effectiveness context-dependent.

Tirzepatide is a highly effective once-weekly peptide for weight loss, but its higher cost-effectiveness ratio means it may not be the most economical choice in all healthcare settings compared to Semaglutide.

Phentermine-topiramate (Qysmia) offers acceptable cost-effectiveness, particularly in low-resource settings, making it a practical alternative to more expensive drugs.

For patients in low-resource settings, Phentermine-topiramate (Qysmia) is a cost-effective and practical alternative to more expensive obesity medications.

Orlistat is an affordable option with lower effectiveness, making it a practical alternative in resource-limited settings.

Orlistat (120 mg three times daily) is an affordable option for weight loss, but it has lower effectiveness compared to newer drugs like Semaglutide, making it a practical choice primarily in resource-limited settings.

Tirzepatide improves cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, reducing heart failure hospitalizations and improving quality of life.

For patients with obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide (15 mg weekly) has been shown to significantly reduce the risk of heart failure hospitalizations and cardiovascular death. It also improves heart structure and quality of life. This makes it a valuable option for this specific population, in addition to its benefits for diabetes and weight loss.

Tirzepatide is the first pharmacologic therapy approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, significantly reducing the Apnea-Hypopnea Index (AHI).

Tirzepatide (Zepbound) is now approved for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. It significantly reduces the number of breathing interruptions per hour (AHI) by 50-60%. This may lead to less daytime sleepiness and potentially reduced reliance on CPAP machines, though long-term data is still emerging.

Multidisciplinary therapy reduces inflammatory biomarkers (CRP, IL-6, TNF-alpha) and improves the leptin/adiponectin ratio in adults with obesity.

Reducing inflammation is a key benefit of weight loss therapy. By losing weight through a multidisciplinary approach, you can lower levels of inflammatory markers like CRP and IL-6, and improve the balance of hormones like leptin and adiponectin, which protects against cardiovascular disease and other complications.

Bariatric surgery results in greater weight loss and improvement in cardiac troponins compared to intensive lifestyle intervention alone in patients with severe obesity.

For severe obesity, bariatric surgery is more effective than lifestyle changes alone for weight loss and improving heart health markers like cardiac troponins. It is considered when other treatments fail.

Pharmacological interventions, specifically GLP-1 receptor agonists and SGLT2 inhibitors, reduce epicardial adipose tissue (EAT) volume and improve cardiovascular outcomes, often independent of weight loss.

If you have T2DM, obesity, or heart failure, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs can reduce the fat around your heart and improve your heart's function, sometimes even without significant weight loss.

In patients with Type 2 Diabetes, GLP-1RA use is strongly associated with prior use of insulin and multiple oral antidiabetic agents, indicating their role as intensification therapies for poorly controlled diabetes.

If you have Type 2 Diabetes and are already taking insulin or multiple oral medications, your provider is likely to prescribe a GLP-1RA as an intensification therapy. This is a standard and effective approach for managing blood sugar when other treatments are insufficient.

Mandibular advancement devices (MADs) provide symptom relief comparable to CPAP in mild-to-moderate OSA primarily due to superior long-term adherence, despite CPAP's superior objective efficacy in reducing AHI.

If you have mild-to-moderate sleep apnea and struggle with CPAP, ask about a mandibular advancement device. It might not reduce your apnea events as much as CPAP, but you are more likely to use it every night, which often leads to better overall health outcomes and symptom relief.